Bio-Techne Corporation (FRA:TE1)
Germany flag Germany · Delayed Price · Currency is EUR
57.00
+0.50 (0.88%)
Last updated: Jan 28, 2026, 8:02 AM CET

Revenue by Geography

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17 Jun '16 Jun '15 Jun '14 Jun '13 Jun '12
United States Revenue
673.46M683.23M
EMEA ex-UK Revenue
272.37M266.31M
United Kingdom Revenue
54.09M54.83M
APAC ex-Greater China Revenue
78.29M77.26M
Greater China Revenue
100.93M100.46M
Rest of World Revenue
37.60M37.55M
Revenue (Other)
-1.00K-
Revenue (Total)
1.22B1.22B

Revenue

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17 Jun '16 Jun '15 Jun '14 Jun '13 Jun '12
Protein Sciences Revenue
867.90M870.25M
Diagnostics and Genomics Revenue
342.53M346.26M
Other Segment Revenue
-4.15M
Intersegment Revenue
-984.00K-1.03M
Revenue (Other)
7.29M-
Revenue (Total)
1.22B1.22B

EBIT

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17 Jun '16 Jun '15 Jun '14 Jun '13 Jun '12
Protein Sciences Operating Income
367.53M370.35M
Diagnostics and Genomics Operating Income
25.93M21.32M
Operating Income (Total)
109.93M102.26M

Key Performance Indicators

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17 Jun '16 Jun '15 Jun '14 Jun '13 Jun '12
Organic Sales Growth
5.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai.